Iovance Biotherapeutics, Inc. (IOVA) Financial Ratios
18 years of historical data (2008–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
2.00
↓-31% vs avg
5yr avg: 2.89
30Y Low1.4·High127.8
ROE
↓
-55.5%
↓+13% vs avg
5yr avg: -63.8%
30Y Low-82%·High-37%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
IOVA Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Iovance Biotherapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.4B | $976M | $2.1B | $1.9B | $1.0B | $2.9B | $6.4B | $3.4B | $861M | $522M | $384M |
| Enterprise Value | $1.3B | $861M | $2.1B | $1.9B | $871M | $2.9B | $6.4B | $3.4B | $779M | $377M | $218M |
| P/E Ratio → | -3.59 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 5.31 | 3.70 | 13.07 | 1607.75 | — | — | — | — | — | — | — |
| P/B Ratio | 2.00 | 1.40 | 3.02 | 3.27 | 2.04 | 4.71 | 9.77 | 11.51 | 1.85 | 3.59 | 2.30 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
IOVA EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 3.27 | 12.72 | 1574.93 | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
IOVA Profitability
Margins and return-on-capital ratios measuring operating efficiency
Iovance Biotherapeutics, Inc. earns an operating margin of -153.1%. Operating margins have expanded from -38735.0% to -153.1% over the past 3 years, signaling improving operational efficiency. A negative ROE of -55.5% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 97.2% | 97.2% | 24.4% | -804.5% | — | — | — | — | — | — | — |
| Operating Margin | -153.1% | -153.1% | -240.9% | -38735.0% | — | — | — | — | — | — | — |
| Net Profit Margin | -148.4% | -148.4% | -226.8% | -37345.4% | — | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -55.5% | -55.5% | -57.5% | -81.9% | -70.6% | -53.6% | -54.3% | -51.6% | -40.4% | -58.9% | -39.0% |
| ROA | -42.9% | -42.9% | -44.0% | -61.5% | -54.9% | -44.3% | -46.6% | -47.9% | -38.8% | -56.3% | -38.1% |
| ROIC | -48.9% | -48.9% | -49.5% | -76.9% | -61.8% | -40.9% | -41.9% | -45.6% | -50.1% | -25056.7% | -10435.6% |
| ROCE | -51.6% | -51.6% | -54.2% | -74.1% | -63.3% | -48.9% | -51.4% | -53.6% | -41.9% | -59.5% | -39.6% |
IOVA Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $163M exceeds total debt of $48M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.07 | 0.07 | 0.08 | 0.13 | 0.17 | 0.12 | 0.08 | 0.04 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.16 | -0.08 | -0.07 | -0.29 | -0.01 | -0.02 | -0.01 | -0.18 | -1.00 | -1.00 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | -133.63 | — | — | — | — | — | — |
Net cash position: cash ($163M) exceeds total debt ($48M)
IOVA Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Iovance Biotherapeutics, Inc.'s current ratio of 3.20x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 2.83x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has improved from 2.79x to 3.20x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.20 | 3.20 | 3.74 | 2.79 | 5.24 | 5.69 | 11.59 | 8.10 | 33.02 | 15.09 | 34.12 |
| Quick Ratio | 2.83 | 2.83 | 3.31 | 2.70 | 5.24 | 5.69 | 11.59 | 8.10 | 33.02 | 15.09 | 34.12 |
| Cash Ratio | 2.15 | 2.15 | 2.65 | 2.54 | 5.16 | 5.65 | 11.47 | 7.86 | 32.54 | 14.70 | 33.51 |
| Asset Turnover | — | 0.29 | 0.18 | 0.00 | — | — | — | — | — | — | — |
| Inventory Turnover | 0.14 | 0.14 | 2.41 | 1.04 | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 114.21 | 154.26 | 46.35 | — | — | — | — | — | — | — |
IOVA Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Iovance Biotherapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | 12.9% |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.2% | 0.2% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.2% | 13.0% |
| Shares Outstanding | — | $357M | $290M | $235M | $159M | $153M | $138M | $124M | $97M | $65M | $55M |
Peer Comparison
Compare IOVA with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 IOVAYou | $1B | -3.6 | — | — | 97.2% | -153.1% | -55.5% | -48.9% | — |
 ADCT | $139M | -1.0 | — | — | 90.6% | -133.2% | — | — | — |
 FATE | $244M | -1.8 | — | — | -94.1% | -2222.4% | -51.8% | -36.5% | — |
 CRSP | $5B | -8.4 | — | — | -6537.0% | -16191.4% | -30.2% | -22.3% | — |
 NTLA | $2B | -4.1 | — | — | 76.5% | -651.7% | -53.5% | -44.0% | — |
 BEAM | $4B | -42.1 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 TGTX | $8B | 19.2 | 67.4 | — | 83.7% | 20.0% | 102.8% | 16.4% | 2.1 |
 KYMR | $7B | -24.5 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 ALNY | $37B | 119.4 | 65.9 | 79.7 | 81.8% | 13.5% | 73.3% | 33.4% | 2.3 |
 RCUS | $2B | -7.4 | — | — | 96.0% | -156.3% | -63.3% | -64.1% | — |
 IMVT | $7B | -12.8 | — | — | — | — | -64.8% | — | — |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 18 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
IOVA — Frequently Asked Questions
Quick answers to the most common questions about buying IOVA stock.
What is Iovance Biotherapeutics, Inc.'s P/E ratio?
Iovance Biotherapeutics, Inc.'s current P/E ratio is -3.6x. This places it at the 50th percentile of its historical range.
What is Iovance Biotherapeutics, Inc.'s ROE?
Iovance Biotherapeutics, Inc.'s return on equity (ROE) is -55.5%. The historical average is -53.3%.
Is IOVA stock overvalued?
Based on historical data, Iovance Biotherapeutics, Inc. is trading at a P/E of -3.6x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Iovance Biotherapeutics, Inc.'s profit margins?
Iovance Biotherapeutics, Inc. has 97.2% gross margin and -153.1% operating margin.